Healthcare

(PETS) Small Caps, Big Yields

Finding small cap companies that pay a dividend is no easy feat. At this stage in a company’s growth trajectory, cash flow is usually too erratic or is immediately put into growing the company.

However, there are those rare small cap jewels that offer yields above 3%. Aside from master limited...

18Mar2014 | | Comments Off on (PETS) Small Caps, Big Yields | Continued

(NPSP) The Secret to Picking Biotech Stocks

Yesterday, I was on Komodo Island, Indonesia, as part of The Oxford Club’s Chairman’s Circle cruise to Australia and Indonesia.

We saw the famed Komodo dragons, which are some of the most lethal animals in the world. When they bite, they release bacteria that stop the blood-clotting process,...

15Mar2014 | | Comments Off on (NPSP) The Secret to Picking Biotech Stocks | Continued

(CLDX) From the Mailbag: Should You Dump Small Caps?

I’m sorry, James, but I can’t endorse your idea.

If you want to make money in the markets, small caps must be part of your portfolio. They outperform large caps over the long term and will add several percentage points to your overall return.

But small caps are risky, right?

On...

8Mar2014 | | Comments Off on (CLDX) From the Mailbag: Should You Dump Small Caps? | Continued

(ARAY) Accuray Presents Positive Data

Radiosurgery systems maker, Accuray Incorporated (ARAY) published encouraging data about its CyberKnife Robotic Radiosurgery System, which provides stereotactic body radiation therapy (SBRT) to treat prostrate cancer.

Clinical...

7Oct2013 | | Comments Off on (ARAY) Accuray Presents Positive Data | Continued

(PPHM) Peregrine Pharmaceuticals Shows Encouraging News

Peregrine Pharmaceuticals (PPHM) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III registration trial for its oncology candidate,...

26Sep2013 | | Comments Off on (PPHM) Peregrine Pharmaceuticals Shows Encouraging News | Continued

(PFE) Pfizer Halts Inotuzumab Study

Pfizer Inc. (PFE) recently faced a pipeline setback with the company discontinuing a late-stage study being conducted with its oncology candidate, inotuzumab ozogamicin.

The randomized, open-label, two-arm phase III study was...

17Sep2013 | | Comments Off on (PFE) Pfizer Halts Inotuzumab Study | Continued

(STJ) St. Jude Medical Begins EnligHTNment Study

St. Jude Medical Inc. (STJ) commenced the EnligHTNment trial study at the EuroPCR to analyze the effectiveness of its EnligHTN Multi-Electrode Renal Denervation System in reducing major cardiovascular events such as strokes, heart...

15Sep2013 | | Comments Off on (STJ) St. Jude Medical Begins EnligHTNment Study | Continued

(NPSP) NPS Pharmaceuticals Prices Offering

NPS Pharmaceuticals, Inc. (NPSP) recently priced a public offering of 6,000,000 shares at $14.53 a share, with a 30-day over-allotment option for an additional 900,000 shares. NPS Pharma expects to raise approximately $87.2 million...

12Sep2013 | | Comments Off on (NPSP) NPS Pharmaceuticals Prices Offering | Continued

(IPXL) Impax Laboratories Launches Generic Zomig

Impax Laboratories, Inc. (IPXL) recently announced that it has launched its authorized generic version of AstraZeneca’s (AZN) Zomig (zolmitriptan) tablets and...

10Sep2013 | | Comments Off on (IPXL) Impax Laboratories Launches Generic Zomig | Continued

(AZN) Data on AstraZeneca’s Naloxegol

AstraZeneca (AZN) recently presented data on naloxegol (25 mg once daily) from two pivotal phase III studies (KODIAC-04 and -05) at the Digestive Disease Week (DDW) meeting. Top-line results from this study were initially presented...

9Sep2013 | | Comments Off on (AZN) Data on AstraZeneca’s Naloxegol | Continued

(EW) Edwards Lifesciences Sees Promising Data on Sapien XT

World’s leading provider of heart valves and hemodynamic monitoring Edwards Lifesciences Corporation (EW) disclosed positive one-year data on Edwards Sapien XT trans-catheter aortic heart valve from the post-approval study in Europe....

7Sep2013 | | Comments Off on (EW) Edwards Lifesciences Sees Promising Data on Sapien XT | Continued

(ONCY) Oncolytics Biotech Sees Promising Data on Reolysin

Recently, Oncolytics Biotech Inc. (ONCY) reported positive preliminary results from the US phase II trial (REO 020) evaluating the use of oncology candidate, Reolysin in combination with Bristol-Myers Squibb‘s...

1Sep2013 | | Comments Off on (ONCY) Oncolytics Biotech Sees Promising Data on Reolysin | Continued

(MYL) Favorable Verdict for Mylan

Mylan Inc. (MYL) recently announced that the Court of Appeals for the Federal Circuit has issued a favorable verdict for the company in a patent infringement case. The court overturned the decision of the District Court invalidating...

25Aug2013 | | Comments Off on (MYL) Favorable Verdict for Mylan | Continued

(DXCM) DexCom Stays at Neutral

On May 22, 2013, we reiterated DexCom, Inc. (DXCM) at Neutral based on its first quarter 2013 earnings results.

On May 1, DexCom announced results for the reported quarter. The company incurred adjusted loss per share of 16...

22Aug2013 | | Comments Off on (DXCM) DexCom Stays at Neutral | Continued

(ABT) Abbott Laboratories Announces CE Mark for Xpedition 48 Stent System

Abbott Laboratories (ABT) recently announced that it received CE Mark in Europe for its drug eluting stent – Xience Xpedition 48 Everolimus Eluting Coronary Stent System.

Xience Xpedition 48 is the latest addition to Abbott...

21Aug2013 | | Comments Off on (ABT) Abbott Laboratories Announces CE Mark for Xpedition 48 Stent System | Continued

(SLXP) Positive Data on Roche Candidate

Roche (RHHBY) recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study (n=124).

The study is evaluating the efficacy and safety of etrolizumab...

21Aug2013 | | Comments Off on (SLXP) Positive Data on Roche Candidate | Continued

(GSK) UCB Presents Study on Restless Leg Syndrome

UCB (UCBJF) recently presented data from a study showing the effect of Neupro on cardiovascular measures in patients with restless legs syndrome (RLS).

The double-blind, placebo-controlled study showed reduction in total nocturnal...

20Aug2013 | | Comments Off on (GSK) UCB Presents Study on Restless Leg Syndrome | Continued

(PCYC) Synageva BioPharma Candidate Earns FDA Breakthrough Therapy Designation

Synageva BioPharma Corp. (GEVA) recently announced that it has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for sebelipase alfa.

Synageva is developing sebelipase alfa for the treatment...

19Aug2013 | | Comments Off on (PCYC) Synageva BioPharma Candidate Earns FDA Breakthrough Therapy Designation | Continued

(AMAG) AMAG Pharmaceuticals Partner Takeda Pharmaceutical Recalls Batch of Rienso

AMAG Pharmaceuticals Inc. (AMAG) has been recently informed by partner, Takeda Pharmaceutical (TKPYY), that the latter is recalling a specific batch of Rienso from...

19Aug2013 | | Comments Off on (AMAG) AMAG Pharmaceuticals Partner Takeda Pharmaceutical Recalls Batch of Rienso | Continued

(NVO) Novo Nordisk’s N9-GP See Positive Test Results

Novo Nordisk (NVO) recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study.

Paradigm 2 evaluated N9-GP, a long-acting FIX derivative, for on-demand or prophylactic treatment...

19Aug2013 | | Comments Off on (NVO) Novo Nordisk’s N9-GP See Positive Test Results | Continued

(ACT) Actavis to Buy Warner Chilcott

Actavis, Inc. (ACT) recently announced its intention to acquire Warner Chilcott plc (WCRX) in a stock-for-stock transaction worth about $8.5 billion. This includes...

19Aug2013 | | Comments Off on (ACT) Actavis to Buy Warner Chilcott | Continued

(ELN) Elan Provides Strategic Update

Elan Corporation (ELN) recently provided an update on its strategic plans for the future. The company plans several acquisitions and has other strategic initiatives lined up for further advancement.

Elan is set to acquire privately...

15Aug2013 | | Comments Off on (ELN) Elan Provides Strategic Update | Continued

(MRK) Merck Enters into Strategic Deal

In an attempt to boost shareholders’ value, Merck & Co. Inc. (MRK) – the N.J. based major drug manufacturer – entered into an agreement with The Goldman Sachs Group, Inc. (GS)...

13Aug2013 | | Comments Off on (MRK) Merck Enters into Strategic Deal | Continued

(THOR) Thoratec Controller Earns Food and Drug Administration Approval

Thoratec Corp. (THOR), a leader in mechanical circulation support devices, recently revealed that it has received approval from the Food and Drug Administration (FDA) to sell the HeartMate II Pocket Controller meant for use with the...

12Aug2013 | | Comments Off on (THOR) Thoratec Controller Earns Food and Drug Administration Approval | Continued

(PKI) PerkinElmer Downgraded to Underperform

On May 16, 2013, we downgraded our recommendation on PerkinElmer Inc. (PKI) to Underperform based on its first quarter earnings results and reduced guidance.

On Apr 25, PerkinElmer announced its results for the reported quarter....

12Aug2013 | | Comments Off on (PKI) PerkinElmer Downgraded to Underperform | Continued

(VOLC) Volcano Corporation Product Launch at EuroPCR

Recently, Volcano Corporation (VOLC) disclosed its plan to feature its innovative technologies, including the company’s Fractional Flow Reserve (FFR) and iFR (Instant Wave-Free Ratio) technologies at the EuroPCR 2013 in Paris.

At...

8Aug2013 | | Comments Off on (VOLC) Volcano Corporation Product Launch at EuroPCR | Continued

(XNPT) XenoPort Candidate Disappoints

XenoPort, Inc. (XNPT) recently reported disappointing results on arbaclofen placarbil (AP) from a pivotal late-stage study (n=228).

Results from the phase III trial showed that AP failed to achieve statistically significant...

7Aug2013 | | Comments Off on (XNPT) XenoPort Candidate Disappoints | Continued

(GILD) Gilead’s Sofosbuvir under European Review

Gilead Sciences Inc. (GILD) recently announced that its Marketing Authorisation Application (MAA) for HCV candidate sofosbuvir (formerly GS-7977), submitted to the European Medicines Agency (EMA) on Apr 17, 2013, has been validated...

4Aug2013 | | Comments Off on (GILD) Gilead’s Sofosbuvir under European Review | Continued

(XNPT) XenoPort Resumes Horizant Supply

XenoPort Inc. (XNPT) recently commenced shipments of Horizant extended-release tablets in the US. The drug is approved in the US for the treatment of moderate-to-severe primary restless legs syndrome (RLS) as well as for the management...

4Aug2013 | | Comments Off on (XNPT) XenoPort Resumes Horizant Supply | Continued

(SNY) Sanofi and Regeneron Pharmaceuticals Dupilumab Data Published

Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) recently announced that positive data from a phase IIa study evaluating dupilumab (REGN668/SAR231893)...

4Aug2013 | | Comments Off on (SNY) Sanofi and Regeneron Pharmaceuticals Dupilumab Data Published | Continued